Wells Fargo analyst David Maris noted that the FDA announced this morning that it is streamlining the labeling for naloxone to enable drug makers to produce over-the-counter versions, which he views as potentially positive for Amphastar (AMPH), which makes injectable naloxone and is working on a nasal spray, and possibly negative for Emergent BioSolutions (EBS), which acquired Adapt Pharma, the producer of NARCAN nasal spray. A generic OTC version of naloxone could come at a much cheaper price point than Evzio, which is priced at $4,100, or NARCAN, priced at $125, said Maris. He has a Market Perform rating on Emergent shares and an Outperform rating on Amphastar.